January 1996
·
5 Reads
Journal of Allergy and Clinical Immunology
This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.
January 1996
·
5 Reads
Journal of Allergy and Clinical Immunology
January 1995
·
2 Reads
Journal of Allergy and Clinical Immunology
January 1993
·
19 Reads
Journal of Allergy and Clinical Immunology
May 1990
·
129 Reads
·
31 Citations
Annals of Allergy
Hereditary angioedema (HAE) is an inherited deficiency of C1 esterase inhibitor (C1 inh). The two types of genetic C1 inh deficiency are type I, which is quantitative, and type II, which is functional. For the purpose of the present study, four HAE patients were selected. None of them had received any androgenic therapy. The group included three type I and one type II cases. All patients that entered the protocol received danazol, 400 mg/day for 14 days. The complement system was evaluated by monitoring C4, hemolytic complement 50% (CH50), circulating immune complexes (CIC), and antigenic and functional C1 inh during the study. The level of complement factors at the beginning and at the end of this period demonstrated a statistically significant increase in C4 and CH50 and the disappearance of CIC, while C1 inh remained unmodified. These results suggest that the therapeutic effect of danazol may have two mechanisms of action: (1) promotion of C4 synthesis by anabolic effect resulting in an improvement of the complement system with the disappearance of CIC and (2) a minor increase in C1 inh level primarily due to the lack of its consumption.
May 1989
·
68 Reads
·
2 Citations
Hereditary angioedema (HAE) is an inherited deficiency of the inhibitor of C1 esterase (C1 inh). Two types of genetic C1 inh deficiency have been described, type I: quantitative, and type II: functional. For the purpose of the present study, 4 out of 51 HAE patients were selected. None of them had received any previous androgenic therapy. The group was integrated by two type I and one type II cases. All patients that entered in the protocol received 400 mg/day of danazol over 14 days. The complement system was evaluated by monitoring C4, Hemolytic complement 50% (CH50), Circulating Immune Complexes (CIC), and antigenic and functional C1 INH during the study. The level of the complement factors at the beginning and the end of this period demonstrated a statistically significant increase of C4 and CH50 and the disappearance of CIC, while C1INH remained unmodified. These results suggest that the therapeutic effect of Danazol may have two mechanisms of action: i. promotion of C4 synthesis by anabolic effect resulting in an improvement of the complement system with the disappearance of CIC, and ii, a minor increase of C1 inh level primarily due to the lack of its consumption.
... 1 2 tip anjioödem olup bunlar herediter ve kazanılmış olarak sınıflandırılır. 2 Herediter anjioödem (HAÖ) klasik kompleman sisteminin başlangıç proteinlerini regüle eden C1 inhibitör protein defektine bağlı olarak gelişen, nadir görülen kalıtsal bir hastalıktır. [3][4][5] Herediter anjioödemin 3 farklı tipi bulunmaktadır. Herediter anjiyoödem olgularının % 85'ini C1 INH enzim düzeyi düşüklünün görüldüğü tip I oluşturmaktadır. ...
May 1990
Annals of Allergy
... Prophylactically, HAE can be managed with regular C1-inhibitor replacement therapy (preferred) or an androgen such as danazol or stanozolol. Danazol is thought to work by promoting the synthesis of the C4 complement protein, resulting in a modest increase in the C1-INH level [9]. The use of anabolic steroids, such as danazol and stanozolol, has steadily decreased over the past decade in favor of more pathway-specific options, such as C1 esterase inhibitors [10]. ...
Reference:
Hereditary Angioedema
May 1989